Later work showed that Mir143 has a tumor suppressor role in prostate cancer by controlling cell proliferation and survival through modulation of ERK5 [74], and that Mir143 expression inversely correlates with nuclear ERK5 immunoreactivity in clinical prostate cancer [75]. Here, MAPK7 is linked to prostate carcinoma.